NO20033651L - Cancerbehandling - Google Patents

Cancerbehandling

Info

Publication number
NO20033651L
NO20033651L NO20033651A NO20033651A NO20033651L NO 20033651 L NO20033651 L NO 20033651L NO 20033651 A NO20033651 A NO 20033651A NO 20033651 A NO20033651 A NO 20033651A NO 20033651 L NO20033651 L NO 20033651L
Authority
NO
Norway
Prior art keywords
cancer treatment
treatment
possibly
combination
chemotherapeutic agent
Prior art date
Application number
NO20033651A
Other languages
English (en)
Other versions
NO333105B1 (no
NO20033651D0 (no
Inventor
Heidi Lane
Terence O'reilly
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033651(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20033651D0 publication Critical patent/NO20033651D0/no
Publication of NO20033651L publication Critical patent/NO20033651L/no
Publication of NO333105B1 publication Critical patent/NO333105B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Rapamycinderivater har interessante effekter ved behandling av solide tumorer, eventuelt i kombinasjon med et kjemoterapeutisk middel.
NO20033651A 2001-02-19 2003-08-18 Anvendelse av 40-0-(2-hydroxyetyl)-rapamycin til fremstilling av en farmasøytisk sammensetning til bruk i cancerbehandling NO333105B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
PCT/EP2002/001714 WO2002066019A2 (en) 2001-02-19 2002-02-18 Cancer treatment

Publications (3)

Publication Number Publication Date
NO20033651D0 NO20033651D0 (no) 2003-08-18
NO20033651L true NO20033651L (no) 2003-10-17
NO333105B1 NO333105B1 (no) 2013-03-04

Family

ID=26245731

Family Applications (14)

Application Number Title Priority Date Filing Date
NO20033651A NO333105B1 (no) 2001-02-19 2003-08-18 Anvendelse av 40-0-(2-hydroxyetyl)-rapamycin til fremstilling av en farmasøytisk sammensetning til bruk i cancerbehandling
NO20120451A NO335134B1 (no) 2001-02-19 2012-04-18 Farmasøytisk kombinasjon omfattende 40-O-(2-hydroksyetyl)-rapamycin samt ko-middelet exemestan samt anvendelse derav
NO20130045A NO334646B1 (no) 2001-02-19 2013-01-09 Anvendelse av 40-O-(2-hydroksyetyl)rapamycin i kombinasjon med et komiddel, farmasøytisk kombinasjon samt farmasøytisk sammensetning for terapeutisk eller profylaktisk behandling av faste tumorer
NO20131544A NO336208B1 (no) 2001-02-19 2013-11-19 40-O-(2-hydroksyetyl)-rapamycin for anvendelse i behandling av faste tumorer i ekskresjonssystemet samt farmasøytisk sammensetning
NO20131547A NO336581B1 (no) 2001-02-19 2013-11-19 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin for fremstilling av et farmasøytisk medikament for administrering av medikamentet sammen med letrozol for å inhibere vekst av faste bryst tumorer hos et individ
NO20131545A NO336428B1 (no) 2001-02-19 2013-11-19 40-O-(2-hydroksksyethyl)-rapamycin alene for anvendelse ved behandling av faste hjernetumorer og en farmasøytisk sammensetning omfattende denne
NO20131546A NO336110B1 (no) 2001-02-19 2013-11-19 Anvendelse av rapamycin og derivater derav i kombinasjon med paclitaxel for fremstilling av et farmasøytisk medikament for behandling av faste bryst tumorer
NO2015010C NO2015010I1 (no) 2001-02-19 2015-03-18 Everolimus - se vedlegg til søknad
NO20150413A NO20150413L (no) 2001-02-19 2015-04-09 Cancerbehandling
NO20150831A NO340553B1 (no) 2001-02-19 2015-06-24 40-O-(2-hydroksyetyl)-rapamycin for anvendelse i behandling av hormonreseptor positiv brysttumor i kombinasjon med exemestan
NO20150895A NO339240B1 (no) 2001-02-19 2015-07-08 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin samt farmasøytisk sammensetning inneholdende dette i forebygging, forsinkelse av progresjon eller behandling av brystcancer i kombinasjon med letrozol
NO20161348A NO340924B1 (no) 2001-02-19 2016-08-24 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av faste tumorer i lunger annet enn lymfekreft
NO20170803A NO343599B1 (no) 2001-02-19 2017-05-16 Anvendelse av 40-O-(2-hydroxyetyl)-rapamycin til behandling av fremskredne faste tumorer
NO20190290A NO20190290A1 (no) 2001-02-19 2019-03-04 Cancerbehandling

Family Applications After (13)

Application Number Title Priority Date Filing Date
NO20120451A NO335134B1 (no) 2001-02-19 2012-04-18 Farmasøytisk kombinasjon omfattende 40-O-(2-hydroksyetyl)-rapamycin samt ko-middelet exemestan samt anvendelse derav
NO20130045A NO334646B1 (no) 2001-02-19 2013-01-09 Anvendelse av 40-O-(2-hydroksyetyl)rapamycin i kombinasjon med et komiddel, farmasøytisk kombinasjon samt farmasøytisk sammensetning for terapeutisk eller profylaktisk behandling av faste tumorer
NO20131544A NO336208B1 (no) 2001-02-19 2013-11-19 40-O-(2-hydroksyetyl)-rapamycin for anvendelse i behandling av faste tumorer i ekskresjonssystemet samt farmasøytisk sammensetning
NO20131547A NO336581B1 (no) 2001-02-19 2013-11-19 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin for fremstilling av et farmasøytisk medikament for administrering av medikamentet sammen med letrozol for å inhibere vekst av faste bryst tumorer hos et individ
NO20131545A NO336428B1 (no) 2001-02-19 2013-11-19 40-O-(2-hydroksksyethyl)-rapamycin alene for anvendelse ved behandling av faste hjernetumorer og en farmasøytisk sammensetning omfattende denne
NO20131546A NO336110B1 (no) 2001-02-19 2013-11-19 Anvendelse av rapamycin og derivater derav i kombinasjon med paclitaxel for fremstilling av et farmasøytisk medikament for behandling av faste bryst tumorer
NO2015010C NO2015010I1 (no) 2001-02-19 2015-03-18 Everolimus - se vedlegg til søknad
NO20150413A NO20150413L (no) 2001-02-19 2015-04-09 Cancerbehandling
NO20150831A NO340553B1 (no) 2001-02-19 2015-06-24 40-O-(2-hydroksyetyl)-rapamycin for anvendelse i behandling av hormonreseptor positiv brysttumor i kombinasjon med exemestan
NO20150895A NO339240B1 (no) 2001-02-19 2015-07-08 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin samt farmasøytisk sammensetning inneholdende dette i forebygging, forsinkelse av progresjon eller behandling av brystcancer i kombinasjon med letrozol
NO20161348A NO340924B1 (no) 2001-02-19 2016-08-24 Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av faste tumorer i lunger annet enn lymfekreft
NO20170803A NO343599B1 (no) 2001-02-19 2017-05-16 Anvendelse av 40-O-(2-hydroxyetyl)-rapamycin til behandling av fremskredne faste tumorer
NO20190290A NO20190290A1 (no) 2001-02-19 2019-03-04 Cancerbehandling

Country Status (27)

Country Link
US (10) US8410131B2 (no)
EP (11) EP2783686B1 (no)
JP (14) JP2004525899A (no)
KR (3) KR20070102762A (no)
CN (5) CN1551767A (no)
AU (1) AU2002250968C1 (no)
BR (1) BR0207378A (no)
CA (3) CA2438504C (no)
CY (11) CY1116616T1 (no)
CZ (5) CZ309178B6 (no)
DK (6) DK2269603T3 (no)
ES (8) ES2629317T3 (no)
HK (7) HK1250336B (no)
HU (1) HUP0303271A3 (no)
IL (13) IL157425A0 (no)
LT (9) LT3351246T (no)
LU (3) LU92880I2 (no)
MX (3) MX368013B (no)
NO (14) NO333105B1 (no)
NZ (1) NZ527692A (no)
PL (5) PL363918A1 (no)
PT (7) PT2762140T (no)
RU (8) RU2322981C2 (no)
SI (6) SI2762140T1 (no)
SK (5) SK288545B6 (no)
TW (2) TWI334350B (no)
WO (1) WO2002066019A2 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
SI2762140T1 (sl) 2001-02-19 2017-07-31 Novartis Ag Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP2301551A1 (de) 2002-07-30 2011-03-30 Aeterna Zentaris Gmbh Anwendung von Alkylphosphocholinen in kombination mit Antitumormedikamenten
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2005215910B2 (en) * 2004-02-23 2008-05-01 Novartis Ag P53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
BRPI0508959A (pt) * 2004-03-23 2007-08-14 Astrazeneca Ab uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1848431B1 (en) 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
EP2253320A1 (en) * 2005-07-20 2010-11-24 Novartis AG Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
NO20220050A1 (no) * 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
HUE037890T2 (hu) 2006-02-02 2018-09-28 Novartis Ag Sclerosis tuberosa kezelése
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
PT2481409T (pt) * 2007-03-07 2018-10-18 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
US20110229572A1 (en) * 2007-08-16 2011-09-22 Biocompatibles Uk Limited Delivery of drug combinations
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009126965A2 (en) * 2008-04-11 2009-10-15 The Regents Of The University Of Colorado Compositions, methods and uses for modulations of brca1
BRPI0916904A2 (pt) * 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP3354293B1 (en) 2012-05-23 2019-12-11 Smith & Nephew plc Apparatuses for negative pressure wound therapy
CN104661626B (zh) 2012-08-01 2018-04-06 史密夫及内修公开有限公司 伤口敷料
HUE033329T2 (en) 2012-08-01 2017-11-28 Smith & Nephew dressing
US10493184B2 (en) 2013-03-15 2019-12-03 Smith & Nephew Plc Wound dressing and method of treatment
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
HRP20211976T1 (hr) * 2015-08-17 2022-03-18 Kura Oncology, Inc. Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze
CA3016446A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3644914A1 (en) 2017-06-30 2020-05-06 T J Smith & Nephew Limited Negative pressure wound therapy apparatus
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) * 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
TW225528B (no) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
AU5151093A (en) 1992-10-14 1994-05-09 Unichema Chemie Bv Process for the preparation of alkylglycosides
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
HU228234B1 (en) * 1995-06-09 2013-02-28 Novartis Ag Rapamycin derivatives, pharmaceutical compositions containing them and their use
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
ES2193379T3 (es) * 1996-06-11 2003-11-01 Novartis Ag Combinacion de un analogo de somatostatina y de una rapamicina.
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
JP2001500126A (ja) 1996-09-09 2001-01-09 アメリカン・ホーム・プロダクツ・コーポレイション アルキル化ラパマイシン誘導体
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
KR100440553B1 (ko) 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
ATE363275T1 (de) * 1998-04-27 2007-06-15 Astellas Pharma Inc Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
DE60012192T2 (de) 1999-08-18 2005-09-08 Wyeth Wasserlösliche sdz-rad ester
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
AU3095601A (en) 2000-01-14 2001-07-24 Univ Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
EP1318837B1 (en) 2000-08-11 2004-10-06 Wyeth Method of treating estrogen receptor positive carcinoma
WO2002022133A1 (en) * 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
KR20030045847A (ko) 2000-10-31 2003-06-11 쿡 인코포레이티드 코팅된 이식형 의료 장치
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1355588B1 (en) * 2000-12-22 2007-08-15 Avantec Vascular Corporation Device for delivery of therepeutic agents
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
SI2762140T1 (sl) 2001-02-19 2017-07-31 Novartis Ag Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina
SG152906A1 (en) 2001-04-06 2009-06-29 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
BR112013032887B1 (pt) 2011-07-01 2020-10-06 Coloplast A/S Cateter retal
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
JP6383814B2 (ja) 2018-08-29
JP6310970B2 (ja) 2018-04-11
CA2438504C (en) 2016-02-16
KR100695846B1 (ko) 2007-03-19
SI2762140T1 (sl) 2017-07-31
CY2019043I1 (el) 2020-05-29
EP1363627A2 (en) 2003-11-26
ES2744377T3 (es) 2020-02-24
CN104083365A (zh) 2014-10-08
CZ309247B6 (cs) 2022-06-22
CY2019030I1 (el) 2020-05-29
EP2269604A1 (en) 2011-01-05
CZ2010473A3 (no) 2004-01-14
BR0207378A (pt) 2004-06-15
IL229160A0 (en) 2013-12-31
JP5879391B2 (ja) 2016-03-08
CY2015044I2 (el) 2017-03-15
RU2006140514A (ru) 2008-05-27
HK1146245A1 (zh) 2011-05-27
EP3406249A1 (en) 2018-11-28
PL414996A1 (pl) 2016-02-29
IL229160B (en) 2018-08-30
RU2445093C2 (ru) 2012-03-20
NO20131544L (no) 2003-10-17
HUP0303271A3 (en) 2010-09-28
EP3351246B8 (en) 2019-09-18
SK10382003A3 (sk) 2004-03-02
PT2269604T (pt) 2016-11-04
JP2014208657A (ja) 2014-11-06
CN1551767A (zh) 2004-12-01
ES2629317T3 (es) 2017-08-08
SK288630B6 (sk) 2019-01-08
DK2269603T3 (en) 2015-08-24
US8778962B2 (en) 2014-07-15
PL415000A1 (pl) 2016-02-29
JP2014193901A (ja) 2014-10-09
US20160303092A1 (en) 2016-10-20
IL259724A (en) 2018-08-30
JP6349474B2 (ja) 2018-06-27
PL414997A1 (pl) 2016-02-29
DK3351246T3 (da) 2019-06-03
CY1118316T1 (el) 2017-04-05
NO336208B1 (no) 2015-06-15
KR20040007451A (ko) 2004-01-24
LTPA2019511I1 (lt) 2019-06-25
JP2016222705A (ja) 2016-12-28
RU2011138835A (ru) 2013-03-27
NO20130045L (no) 2003-10-17
NO2015010I1 (no) 2015-03-30
JP2018100281A (ja) 2018-06-28
RU2013143306A (ru) 2015-03-27
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
SI2269604T1 (sl) 2016-11-30
MXPA03007418A (es) 2003-11-18
EP2762140B1 (en) 2017-03-22
EP2764865A3 (en) 2014-10-01
DK3342411T3 (da) 2019-09-02
WO2002066019A3 (en) 2002-10-24
IL251270B (en) 2018-06-28
CZ2018211A3 (no) 2004-01-14
HK1146247A1 (en) 2011-05-27
EP2764865A2 (en) 2014-08-13
AU2002250968B2 (en) 2006-01-12
JP2018100283A (ja) 2018-06-28
CY2016047I2 (el) 2017-04-05
EP3143995B1 (en) 2018-12-05
SK288834B6 (sk) 2021-03-10
LTC2269604I2 (lt) 2020-01-27
TW200626151A (en) 2006-08-01
NO334646B1 (no) 2014-05-05
US20120214774A1 (en) 2012-08-23
WO2002066019A2 (en) 2002-08-29
NO336428B1 (no) 2015-08-17
NO20131546L (no) 2003-10-17
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
KR100695846B9 (ko) 2021-09-30
RU2322981C2 (ru) 2008-04-27
LTPA2020503I1 (lt) 2020-03-10
NZ527692A (en) 2005-05-27
LU93320I2 (fr) 2017-01-30
LUC00122I1 (no) 2019-06-06
NO333105B1 (no) 2013-03-04
US8877771B2 (en) 2014-11-04
EP3345602A1 (en) 2018-07-11
LT3351246T (lt) 2019-07-10
NO340924B1 (no) 2017-07-17
IL259724B (en) 2021-12-01
NO336581B1 (no) 2015-09-28
PT3345602T (pt) 2022-07-04
JP2018168188A (ja) 2018-11-01
EP2783686B1 (en) 2017-06-21
NO20150895L (no) 2003-10-17
JP5775022B2 (ja) 2015-09-09
LTPA2016035I1 (lt) 2016-12-27
HK1250336B (zh) 2020-02-07
SK288524B6 (sk) 2018-01-04
SI3351246T1 (sl) 2019-08-30
EP3345602B1 (en) 2022-04-06
RU2003127391A (ru) 2005-03-27
EP3342411B1 (en) 2019-08-21
US20120283285A1 (en) 2012-11-08
SK288545B6 (sk) 2018-03-05
JP6904640B2 (ja) 2021-07-21
PT3351246T (pt) 2019-06-07
US20130287769A1 (en) 2013-10-31
NO20131547L (no) 2003-10-17
CA2438504A1 (en) 2002-08-29
US20130059877A1 (en) 2013-03-07
NO20150413L (no) 2003-10-17
CY1116616T1 (el) 2017-03-15
PL363918A1 (en) 2004-11-29
CN1679559A (zh) 2005-10-12
IL220096A0 (en) 2012-07-31
CZ200591A3 (cs) 2019-01-23
NO20150831A1 (no) 2015-06-24
CZ309178B6 (cs) 2022-04-20
CY1121314T1 (el) 2020-05-29
JP2007284454A (ja) 2007-11-01
JP6333766B2 (ja) 2018-05-30
JP2020143134A (ja) 2020-09-10
NO20131545L (no) 2003-10-17
HK1250019A1 (zh) 2018-11-23
EP2269604B1 (en) 2016-07-27
EP2783686A1 (en) 2014-10-01
CA2860306A1 (en) 2002-08-29
JP2014177469A (ja) 2014-09-25
CY1121715T1 (el) 2020-05-29
EP2762140A1 (en) 2014-08-06
NO20161348A1 (no) 2016-08-24
EP2783686A8 (en) 2015-03-04
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
CY2015044I1 (el) 2017-03-15
MX368013B (es) 2019-09-13
DK2762140T3 (en) 2017-07-10
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
SI2269603T1 (sl) 2015-08-31
ES2728739T3 (es) 2019-10-28
LT2762140T (lt) 2017-06-26
JP2017081979A (ja) 2017-05-18
NO20170803A1 (no) 2003-10-17
JP5873128B2 (ja) 2016-03-01
RU2005105664A (ru) 2006-08-10
ES2600304T3 (es) 2017-02-08
US20140105895A1 (en) 2014-04-17
CN1296043C (zh) 2007-01-24
MX2019010879A (es) 2019-12-16
EP3143995A1 (en) 2017-03-22
IL202155A0 (en) 2010-06-16
IL229159A0 (en) 2013-12-31
US20130244951A1 (en) 2013-09-19
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
CZ303611B6 (cs) 2013-01-09
IL250676A0 (en) 2017-03-30
KR20070102762A (ko) 2007-10-19
CZ20032209A3 (cs) 2004-01-14
KR20050095906A (ko) 2005-10-04
NO343599B1 (no) 2019-04-08
PT3143995T (pt) 2019-01-17
IL220096A (en) 2015-10-29
CY1119029T1 (el) 2018-01-10
LUC00122I2 (no) 2019-12-24
LT3342411T (lt) 2019-09-25
SK902019A3 (no) 2004-03-02
PT2762140T (pt) 2017-07-04
RU2013119705A (ru) 2014-11-10
JP2004525899A (ja) 2004-08-26
ES2543383T3 (es) 2015-08-18
IL202155A (en) 2013-04-30
RU2018127821A (ru) 2020-01-30
CZ307637B6 (cs) 2019-01-23
IL220095A0 (en) 2012-07-31
IL250676B (en) 2018-06-28
PL409579A1 (pl) 2015-03-02
IL229156A (en) 2017-02-28
SK288546B6 (sk) 2018-03-05
CY1121983T1 (el) 2020-05-29
HK1198946A1 (en) 2015-06-19
LT2269604T (lt) 2016-11-10
US8410131B2 (en) 2013-04-02
RU2018121314A3 (no) 2021-10-06
US20130253000A1 (en) 2013-09-26
NO20120451L (no) 2003-10-17
CA2994779A1 (en) 2002-08-29
DK2269604T3 (en) 2016-11-14
US20130296359A1 (en) 2013-11-07
EP3342411A1 (en) 2018-07-04
JP6349476B2 (ja) 2018-06-27
SI3342411T1 (sl) 2019-10-30
NO20033651D0 (no) 2003-08-18
HK1197723A1 (zh) 2015-02-13
NO340553B1 (no) 2017-05-08
IL229157A0 (en) 2013-12-31
JP2012184238A (ja) 2012-09-27
IL229156A0 (en) 2013-12-31
CN104274442A (zh) 2015-01-14
CA2860306C (en) 2018-04-17
SI3143995T1 (sl) 2019-02-28
CY2016047I1 (el) 2017-04-05
NO336110B1 (no) 2015-05-18
CY2019030I2 (el) 2020-05-29
CZ307940B6 (cs) 2019-09-04
EP2269603B1 (en) 2015-05-20
DK3143995T3 (en) 2019-01-28
CY2020005I1 (el) 2020-05-29
PT3342411T (pt) 2019-09-19
LU92880I2 (fr) 2016-11-17
JP2015145411A (ja) 2015-08-13
CA2994779C (en) 2020-08-25
NO20190290A1 (no) 2003-10-17
LT3143995T (lt) 2019-01-25
ES2705016T3 (es) 2019-03-21
CZ2019248A3 (cs) 2004-01-14
NO335134B1 (no) 2014-09-22
IL157425A0 (en) 2004-03-28
CN104116738A (zh) 2014-10-29
AU2002250968C1 (en) 2018-01-04
IL229158A (en) 2017-03-30
HK1250018B (zh) 2020-04-17
US8436010B2 (en) 2013-05-07
JP6349475B2 (ja) 2018-06-27
RU2659725C2 (ru) 2018-07-03
PT2269603E (pt) 2015-09-09
PL231418B1 (pl) 2019-02-28
ES2921798T3 (es) 2022-08-31
TWI334350B (en) 2010-12-11
IL220095A (en) 2017-05-29
EP2269603A1 (en) 2011-01-05
HUP0303271A2 (hu) 2004-01-28
JP2018100282A (ja) 2018-06-28
US20040147541A1 (en) 2004-07-29
IL157425A (en) 2013-10-31
IL229158A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
NO20033651L (no) Cancerbehandling
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
MY139743A (en) (2-carboxamido)(3-amino) thiophene compounds
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
NO20070782L (no) Tetrapeptidanaloger.
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
NO20055565D0 (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
UA85559C2 (en) Aminobenzophenone compounds
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
ATE386742T1 (de) Imidazonaphthyridine
WO2005000204A3 (en) Pancreatic cancer treatment
TW200621237A (en) [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
EP1364652A4 (en) CURE FOR LUNG CANCER
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
TR200302193T4 (tr) Kombinasyon kemoterapisi.
NO20041537L (no) Fremgangsmate ved fremstilling av 14beta-hydroksy-baccatin III-1, 14-karbonat
AU2001247560A1 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AU2003288263A1 (en) Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer
SI1663244T1 (sl) Pteridinski derivati za zdravljenje bolezni, povezanih s TNF-alfa
ZA200408071B (en) Combination therapy for the treatment of cancer.
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS PHARMA AG, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS PHARMA AG, CH

MK1K Patent expired